General Information of Drug (ID: DM2TESM)

Drug Name
EPZ028862 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Preclinical [1]
Cross-matching ID
PubChem CID
118947282
TTD Drug ID
DM2TESM

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
EPZ031686 DM8UKL0 Solid tumour/cancer 2A00-2F9Z Preclinical [2]
EPZ0330456 DMUKVYL Colon cancer 2B90.Z Preclinical [1]
GSK2807 DMAZROV Solid tumour/cancer 2A00-2F9Z Preclinical [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histone-lysine N-methyltransferase SMYD3 (SMYD3) TTKLJYX SMYD3_HUMAN Inhibitor [1]

References

1 Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
2 Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents. Expert Opin Ther Targets. 2017 Feb;21(2):145-157.
3 Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets. Structure. 2016 May 3;24(5):774-781.